Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venetoclax

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

AbbVie and Umoja announce CAR-T cell therapy agreements worth over $1.4bn

One of the deals gives AbbVie licensing rights to Umoja's CD19-directed therapy for blood cancers

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed each year in Europe

- PMLiVE

Roche shares positive late-stage results for inavolisib combination in advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

AbbVie to expand neuroscience pipeline with $8.7bn Cerevel Therapeutics acquisition

The deal includes a candidate currently in phase 3 testing as a treatment for Parkinson’s disease

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

Kite and Arcellx expand cell therapy partnership in deal worth over $285m

The companies' existing CART-ddBCMA collaboration now covers lymphomas

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links